Results 21 to 30 of about 74,852 (258)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data

Frontiers in Pharmacology, 2022
Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have ...
Quanfeng Zhao, Pan Ma, Peishu Fu, Jiayu Wang, Jiayu Wang, Kejing Wang, Kejing Wang, Lin Chen, Lin Chen, Yang Yang, Yang Yang   +10 more
doaj   +1 more source

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil

, 2023
To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March
Angelica Nogueira-Rodrigues, Michelle Samora Almeida, Rachel Cossetti, Karime Kalil, Marcela Crosara, Aknar FC Calabrich, Daniele Xavier Assad, Ana Carolina Leite, Andreia C Melo, Carla Rameri de Azevedo, Andrea PG Guimarães, Alessandra Menezes Morelle, Eduardo Cronemberger, Rodrigo Guindalini, Eduardo Paulino, Graziela Dal-Molin, Daniela de Freitas, João Soares Nunes, Poliana Signorini, Fernando C Maluf   +19 more
core   +1 more source

The PARP-1 inhibitor Olaparib causes retention of γ-H2AX foci in BRCA1 heterozygote cells following exposure to gamma radiation [PDF]

, 2013
This article is made available through the Brunel Open Access Publishing Fund. Copyright © 2013 Emma C. Bourton et al. This is an open access article distributed under the Creative Commons Attribution Li-cense, which permits unrestricted use ...
Bourton, EC, Plowman, PN, Adam Zahir, S, Parris, CN, Harvey, AJ   +4 more
core   +1 more source

Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy [PDF]

, 2014
Phosphatase and tensin homolog (PTEN) loss is associated with genomic instability. APE1 is a key player in DNA base excision repair (BER) and an emerging drug target in cancer.
Seedhouse, C, Seedhouse, Claire, Simeonov, Anton, Grabowska, Anna, Jewell, Rosalyn, Nsengimana, J, Ball, G, Abbotts, Rachel, Ball, Graham, Elliott, Faye, Walker, Christy, Wilson III, David M, Wilson III, DM, Patel, Poulam M, Elliott, F, Jadhav, Ajit, Grabowska, A, Laye, J, Simeonov, A, Maloney, DJ, Wilson, DM, Maloney, David J, Madhusudan, Srinivasan, Abbotts, R, Nsengimana, J�r�mie, Jadhav, A, Jewell, R, Madhusudan, S, Walker, C, Patel, PM, Newton-Bishop, J, Laye, Jon, Newton-Bishop, Julia   +32 more
core   +1 more source

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

Frontiers in Oncology, 2021
Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression.
Giacomo Barchiesi, Michela Roberto, Monica Verrico, Patrizia Vici, Silverio Tomao, Federica Tomao, Federica Tomao   +6 more
doaj   +1 more source

Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury

Cells, 2022
Poly(ADP-ribose) polymerase 1 (PARP1), as a potential target for the experimental therapy of acute lung injury (ALI), was identified over 20 years ago.
Vanessa Martins, Sidneia S. Santos, Larissa de O. C. P. Rodrigues, Reinaldo Salomao, Lucas Liaudet, Csaba Szabo   +5 more
doaj   +1 more source

Expanding biomarkers for PARP inhibitors

, 2022
International audienceThe efficacy of talazoparib and other PARP inhibitors has been primarily reported in germline BRCA mutation carriers. New results establish germline mutations in PALB2, but not in other homologous recombination (HR) genes, as ...
Coussy, Florence, Bidard, François Clément   +1 more
core   +1 more source

PARP inhibitors in castration-resistant prostate cancer

Cancer Treatment and Research Communications, 2020
Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA
Abhishek Tripathi, Pragathi Balakrishna, Neeraj Agarwal   +2 more
doaj   +1 more source

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment

Drug Design, Development and Therapy, 2022
Dehua Zhao, Xiaoqing Long, Jisheng Wang Department of Clinical Pharmacy, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang, Sichuan, People’s Republic of ChinaCorrespondence: Dehua Zhao; Jisheng Wang, Email zhaoyaoshi0566@163.com ...
Zhao D, Long X, Wang J
doaj  

PARP Inhibitors in Breast and Ovarian Cancer

, 2023
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most ...
Sim Wey Cheng, Heong Valerie Yue Ming, Yeo Ee Jie, Samuel S. Y. Wang, Goh Liuh Ling   +4 more
core   +1 more source